Deans' stroke musings: Low-dose aspirin after an episode of haemorrhagic stroke is associated with improved survival

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, January 31, 2018

Low-dose aspirin after an episode of haemorrhagic stroke is associated with improved survival

You can ask your doctor exactly what this means. Words are too big for me.
https://www.mdlinx.com/internal-medicine/medical-news-article/2018/01/31/mortality-cohort-studies-aspirin-intracranial-haemorrhages/7501946/?

Thrombosis and Haemostasis — | January 31, 2018

González-Pérez A, et al. - Patients with a history of haemorrhagic stroke (HS) were investigated to assess how antiplatelet drug use affected mortality. Results here suggested an improved survival in association with low-dose aspirin.

Methods

Researchers followed 1,004 patients with intracerebral haemorrhage (ICH) and 929 patients with subarachnoid haemorrhage (SAH), starting 30 days after an HS episode, for amedian of 6.4 years.
The effect of time-dependent exposure to antiplatelets after HS on all-cause mortality was estimated.
They used Cox proportional hazard models to measure adjusted hazard ratios (aHRs) and 95% confidence intervals (CI).

Results

With a similar association among ICH (aHR ¼ 0.66; 95% CI: 0.49–0.89) and SAH (aHR ¼ 0.61; 95% CI: 0.36–1.04) patients, current use of low-dose aspirin was found to be associated with a 32% improved survival (aHR ¼ 0.68; 95% CI: 0.53–0.88).
Individuals who used antithrombotic drugs in the year before the HS showed a statistically significant improved survival associated with current use of low-dose aspirin during follow-up (prior use: aHR ¼ 0.56; 95% CI: 0.39–0.80; non-prior use: aHR ¼ 0.87; 95% CI: 0.61–1.24).
No association of current use of clopidogrel with survival was observed (aHR ¼ 1.35; 95% CI: 0.88–2.08).
Improved survival was evident in association with statin use (aHR ¼ 0.38; 95% CI: 0.31–0.47).
On the other hand, decreased survival was observed in association with discontinuation of statins (aHR ¼ 1.31; 95% CI: 1.02–1.68) or low-dose aspirin (aHR ¼ 1.54; 95% CI: 1.21–1.97).
To reduce vascular risks, use of low-dose aspirin after an episode of HS was safe; this was particularly observed in patients who were on antithrombotic therapy before the episode.